journal
MENU ▼
Read by QxMD icon Read
search

Translational Lung Cancer Research

journal
https://www.readbyqxmd.com/read/30050780/a-consensus-on-immunotherapy-from-the-2017-chinese-lung-cancer-summit-expert-panel
#1
REVIEW
Yi-Long Wu, Chang-Li Wang, Mei-Lin Liao, Zhong-Zhen Guan, Chen-Yan Gao, Shun Lu, Ming-Fang Zhao, Jie Wang, Xiao-Qing Liu, Jin-Ji Yang, Jun Liang, Wei-Min Mao, Bao-Hui Han, Xu-Chao Zhang, Yong Song, Ji-Feng Feng, Sheng-Lin Ma, Gang Wu, Cai-Cun Zhou, Ke-Neng Chen, Ying Cheng, Yong He, Chun Chen, Qun Wang, Ji-Zhen Lin, Bo Zhu, Yun-Peng Liu, Yi Hu, Gui-Bin Qiao, Qing Zhou, Qi-Bin Song, Nan Wu, Lin Wu, Cheng Huang, Xiao-Long Fu, Jian-Ping Xiong, Jie Hu, Cheng-Ping Hu, Jian-Hua Chang, Qiong Zhao, Jun Zhao, Peng-Hui Zhou, Zhi-Yong Ma, Yuan Chen, He-Long Zhang, Fan Yang, Jian-Jun Wang, Yue-Yin Pan, Xue-Ning Yang, Yun Fan, Zhe Liu, Wen Fan, Nong Yang, Yan-Fang Guan, Hao Sun, Wen-Zhao Zhong
The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050779/genome-wide-copy-number-analyses-of-samples-from-lace-bio-project-identify-novel-prognostic-and-predictive-markers-in-early-stage-non-small-cell-lung-cancer
#2
Federico Rotolo, Chang-Qi Zhu, Elisabeth Brambilla, Stephen L Graziano, Ken Olaussen, Thierry Le-Chevalier, Jean-Pierre Pignon, Robert Kratzke, Jean-Charles Soria, Frances A Shepherd, Lesley Seymour, Stefan Michiels, Ming-Sound Tsao
Background: Adjuvant chemotherapy (ACT) provides modest benefit in resected non-small cell lung cancer (NSCLC) patients. Genome-wide studies have identified gene copy number aberrations (CNA), but their prognostic implication is unknown. Methods: DNA from 1,013 FFPE tumor samples from three pivotal multicenter randomized trials (ACT vs. control) in the LACE-Bio consortium (median follow-up: 5.2 years) was successfully extracted, profiled using a molecular inversion probe SNP assay, normalized relative to a pool of normal tissues and segmented...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050778/real-world-data-of-nivolumab-for-previously-treated-non-small-cell-lung-cancer-patients-a-galician-lung-cancer-group-clinical-experience
#3
Mª Carmen Areses Manrique, Joaquín Mosquera Martínez, Jorge García González, Francisco Javier Afonso Afonso, Martín Lázaro Quintela, Natalia Fernández Núñez, Cristina Azpitarte Raposeiras, Margarita Amenedo Gancedo, Lucía Santomé Couto, Mª Rosario García Campelo, Jose Muñoz Iglesias, Alexandra Cortegoso Mosquera, Rocío Vilchez Simo, Joaquín Casal Rubio, Begoña Campos Balea, Iria Carou Frieiro, Guillermo Alonso-Jaudenes Curbera, Urbano Anido Herranz, Jesus García Mata, José Luis Fírvida Pérez
Background: Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivolumab in pretreated NSCLC. Methods: Eligibility criteria included, histologically confirmed NSCLC, stage IIIB and IV, evaluable disease and at least one prior therapy. Patients received nivolumab until progressive disease (PD) or unacceptable toxicity...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050777/the-association-between-human-papillomavirus-presence-and-epidermal-growth-factor-receptor-mutations-in-asian-patients-with-non-small-cell-lung-cancer
#4
Hengrui Liang, Zhenkui Pan, Xiuyu Cai, Wei Wang, Chengye Guo, Jiaxi He, Yuehan Chen, Zhichao Liu, Bo Wang, Jianxing He, Wenhua Liang
Background: The etiology of non-small cell lung cancer (NSCLC) in non-smoker patients remains largely unknown. It has been widely proved that human papillomavirus (HPV) participates in the development of various cancers. Epidermal growth factor receptor (EGFR) mutation patients represent a large portion of non-smokers with NSCLC. We performed this meta-analysis to determine whether HPV infection in NSCLC tissue is associated with EGFR mutations compared with HPV negative controls. Methods: Online databases were searched up to June 30th 2017...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050776/the-prognostic-value-of-metformin-for-advanced-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#5
Jianrong Zhang, Jieyu Wu, Qihua He, Wenhua Liang, Jianxing He
Background: The prognostic value of Metformin for concurrent non-small cell lung cancer (NSCLC) has been controversial in previous individual studies and meta-analyses. In order to further investigate the value of this medication, we conducted a systematic review and meta-analysis for patients with advanced or inoperable NSCLC. Methods: We searched articles from PubMed, Scopus and Web of Science databases; the time interval was from the inception date of the databases to 1 September 2017...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050775/the-180-splice-variant-of-ncam-containing-exon-18-is-specifically-expressed-in-small-cell-lung-cancer-cells
#6
Ann Vander Borght, Mieke Duysinx, Jos L V Broers, Monique Ummelen, Frank W Falkenberg, Christine Hahnel, Bernard A M van der Zeijst
Background: The Neural Cell Adhesion Molecule (NCAM) is a glycoprotein expressed as 120, 140 and/or 180 kDa isoforms, all derived through alternative splicing of a single gene. NCAM 120 contains no intracellular domain, whereas NCAM 140 and 180 have different intracellular domains determined by alternative splicing of exon 18. NCAM has been described as a biomarker to discriminate small cell lung cancer (SCLC) from non-SCLC (NSCLC). However, peripheral blood mononuclear cells (PBMC) also express NCAM...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050774/extrapulmonary-neoplasms-in-lung-cancer-screening
#7
REVIEW
Myrna C B Godoy, Charles S White, Jeremy J Erasmus, Carol C Wu, Mylene T Truong, Reginald F Munden, Caroline Chiles
A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050773/coronary-artery-calcification-in-lung-cancer-screening
#8
REVIEW
James G Ravenel, John W Nance
Lung cancer screening has been shown in the National Lung Screening Trial (NLST) to result in a statistically significant decrease in lung cancer specific mortality. Also within that trial there was shown to be a 7% decrease in all-cause mortality. While the reasons for this benefit are not entirely clear, it may relate to the detection and treatment of other important findings. Smokers not only have a higher risk of lung cancer, but also increased risk of atherosclerosis. The latter can be detected by the discovery of aortic and/or coronary artery calcium on unenhanced CT...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050772/chronic-obstructive-pulmonary-disease-copd-and-lung-cancer-screening
#9
REVIEW
Robert P Young, Raewyn J Hopkins
The primary aim of lung cancer screening is to improve survival from lung cancer by identifying early stage non-small cell lung cancers and prolong survival through their surgical removal. In a post-hoc analysis of 10,054 screening participants from the National Lung Screening Trial (NLST) we show that the risk of lung cancer, according to the PLCOm2012 model, is closely related to the likelihood of having chronic obstructive pulmonary disease (COPD). Those at greatest risk for lung cancer have the highest prevalence of COPD and greater likelihood of dying of a non-lung cancer cause...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050771/the-cytokinesis-blocked-micronucleus-assay-as-a-novel-biomarker-for-selection-of-lung-cancer-screening-participants
#10
Randa A El-Zein, Carol J Etzel, Reginald F Munden
Background: Despite the promising results of the National Lung Screening Trial in reducing lung cancer mortality among high risk smokers, several challenges remain to be addressed. These include the high false positive rates and the large number of smokers screened in order to prevent one lung cancer death. In addition, host genetic susceptibility has not been integrated into selection of who should be screened. These challenges highlight the need to develop robust ways to identify susceptible smokers for appropriate screening...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050770/blood-based-biomarkers-beyond-genomics-for-lung-cancer-screening
#11
REVIEW
Samir M Hanash, Edwin Justin Ostrin, Johannes F Fahrmann
While there is considerable interest at the present time in the development of so-called liquid biopsy approaches for cancer detection based notably on circulating tumor DNA, there are other types of potential biomarkers that show promise for lung cancer screening and early detection. Here we review approaches and some of the promising markers based on proteomics, metabolomics and the immune response to tumor antigens in the form of autoantibodies.
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050769/computer-aided-nodule-analysis-and-risk-yield-canary-characterization-of-adenocarcinoma-radiologic-biopsy-risk-stratification-and-future-directions
#12
REVIEW
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
The majority of incidentally and screen-detected lung cancers are adenocarcinomas. Optimal management of these tumors is clinically challenging due to variability in tumor histopathology and behavior. Invasive adenocarcinoma (IA) is generally aggressive while adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) may be extremely indolent. Computer Aided Nodule Analysis and Risk Yield (CANARY) is a quantitative computed tomography (CT) analysis tool that allows non-invasive assessment of tumor characteristics...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050768/lung-cancer-prediction-using-machine-learning-and-advanced-imaging-techniques
#13
REVIEW
Timor Kadir, Fergus Gleeson
Machine learning based lung cancer prediction models have been proposed to assist clinicians in managing incidental or screen detected indeterminate pulmonary nodules. Such systems may be able to reduce variability in nodule classification, improve decision making and ultimately reduce the number of benign nodules that are needlessly followed or worked-up. In this article, we provide an overview of the main lung cancer prediction approaches proposed to date and highlight some of their relative strengths and weaknesses...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050767/lung-cancer-screening-nodule-identification-and-characterization
#14
REVIEW
Ioannis Vlahos, Konstantinos Stefanidis, Sarah Sheard, Arjun Nair, Charles Sayer, Joanne Moser
The accurate identification and characterization of small pulmonary nodules at low-dose CT is an essential requirement for the implementation of effective lung cancer screening. Individual reader detection performance is influenced by nodule characteristics and technical CT parameters but can be improved by training, the application of CT techniques, and by computer-aided techniques. However, the evaluation of nodule detection in lung cancer screening trials differs from the assessment of individual readers as it incorporates multiple readers, their inter-observer variability, reporting thresholds, and reflects the program accuracy in identifying lung cancer...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050766/appropriate-screening-intervals-in-low-dose-ct-lung-cancer-screening
#15
REVIEW
Marjolein A Heuvelmans, Matthijs Oudkerk
Lung cancer screening by low-dose chest CT (LDCT) is now being implemented in the United States, and in Europe it was recently recommended to start planning for implementation. Current lung cancer screening programmes include up to 25 annual LDCTs, plus shorter-term follow-up LDCTs when indicated. However, the choice of a yearly CT scan has not been based on biological mechanisms, and it is questionable whether all persons eligible for lung cancer screening require annual screening. A tailored approach in screening programs to balance potential harms and benefits from screening becomes more and more important when lung cancer screening is performed more widespread...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050765/the-importance-of-incorporating-smoking-cessation-into-lung-cancer-screening
#16
REVIEW
Jennifer Anne Minnix, Maher Karam-Hage, Janice A Blalock, Paul M Cinciripini
Lung cancer is the leading cause of cancer-related death in the United States (U.S.) and is the second most common non-skin cancer among men and women, accounting for about 30% of cancer-related deaths. There is clear and accumulating evidence that continued tobacco use has multiple adverse effects on cancer treatment outcomes, including greater probability of recurrence, second primary malignancies, reduced survival, greater symptom burden, and poorer quality of life (QOL). Recent findings suggest an avenue to significantly mitigate the impact of smoking on lung cancer mortality rates through the use of low-dose computed tomography (LDCT) lung cancer screening...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050764/shared-decision-making-conversations-and-smoking-cessation-interventions-critical-components-of-low-dose-ct-lung-cancer-screening-programs
#17
REVIEW
Lisa M Lowenstein, Gary M R Deyter, Shawn Nishi, Tianhao Wang, Robert J Volk
Lung cancer remains the world's deadliest cancer despite efforts to decrease smoking rates. Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was shown to reduce lung cancer deaths by 20%. Screening with LDCT comes with potential harms including a high rate of false-positive test results, subsequent follow-up procedures, and radiation exposure. For some patients, the potential benefits associated with screening may be outweighed by the harms. The decision to screen must therefore take into consideration patients' risk of developing lung cancer, comorbidities that may prevent diagnostic procedures or curative surgery, and their values and preferences regarding the benefits and harms of screening...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050763/selecting-lung-cancer-screenees-using-risk-prediction-models-where-do-we-go-from-here
#18
REVIEW
Martin C Tammemägi
The National Lung Screening Trial (NLST) demonstrated that low dose computed tomography (LDCT) screening could reduce lung cancer mortality by 20% in high-risk individuals. The United States Preventive Services Task Force (USPSTF) and Centers for Medicare and Medicaid Services (CMS) approved lung cancer screening. The NLST, USPSTF and CMS define high risk as smoking ≥30 pack-years, smoking within the past 15 years, and being ages 55-74, 55-80 or 55-77. Retrospective studies demonstrated selection using model-estimated risk is superior to NLST-like criteria: higher sensitivity and positive predictive value (PPV), more deaths averted and higher cost-effectiveness...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050762/lung-cancer-screening-with-low-dose-ct-a-world-wide-view
#19
REVIEW
Paul F Pinsky
Lung cancer is the leading cause of cancer death worldwide, comprising almost 20% of all cancer deaths. The concept of screening for lung cancer using low-dose computed tomography (LDCT) dates back almost three decades. This paper reviews the randomized controlled trials and demonstration projects carried out world-wide on LDCT lung cancer screening. Most research has been carried out in North America, Europe and East Asia, regions where lung cancer mortality rates are generally the highest. There are currently no organized national or regional lung cancer screening programs with LDCT...
June 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30050761/the-epidemiology-of-lung-cancer
#20
REVIEW
Patricia M de Groot, Carol C Wu, Brett W Carter, Reginald F Munden
The incidence and mortality from lung cancer is decreasing in the US due to decades of public education and tobacco control policies, but are increasing elsewhere in the world related to the commencement of the tobacco epidemic in various countries and populations in the developing world. Individual cigarette smoking is by far the most common risk factor for lung carcinoma; other risks include passive smoke inhalation, residential radon, occupational exposures, infection and genetic susceptibility. The predominant disease burden currently falls on minority populations and socioeconomically disadvantaged people...
June 2018: Translational Lung Cancer Research
journal
journal
49936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"